Advertisement

Respiratory Viral Infections in Transplant Recipients

  • Catherine LiuEmail author
  • Dora Y. Ho
  • Michael Boeckh
Chapter

Abstract

Respiratory viral infections (RVIs) are common among the general population; however, these often mild viral illnesses can lead to serious morbidity and mortality among recipients of hematopoietic stem cell and solid organ transplantation. The disease spectrum ranges from asymptomatic or mild infections to life-threatening lower respiratory tract infection or long-term airflow obstruction syndromes. Progression to lower respiratory tract infection or to respiratory failure is determined by the intrinsic virulence of the specific viral pathogen as well as various host factors, including the type of transplantation, status of the host’s immune dysfunction, the underlying disease, and other comorbidities. This chapter focuses on the epidemiology, clinical manifestations, diagnosis, and management of RVIs in this susceptible population and includes respiratory syncytial virus, parainfluenza virus, human metapneumovirus, influenza virus, human coronavirus, and human rhinovirus. The optimal management of these infections is limited by the overall paucity of available treatment, highlighting the need for new antiviral drug or immunotherapies.

Keywords

Transplantation Respiratory syncytial virus Parainfluenza virus Human metapneumovirus Influenza virus Human coronavirus Human rhinovirus 

References

  1. 1.
    Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94:1101–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98:573–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Weinberg A, Lyu DM, Li S, Marquesen J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis. 2010;12:330–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24:333–43.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115:2088–94.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7(Suppl):11S–5S.CrossRefPubMedGoogle Scholar
  7. 7.
    Champlin RE, Whimbey E. Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant. 2001;7(Suppl):8S–10S.CrossRefPubMedGoogle Scholar
  8. 8.
    Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85:278–87.CrossRefGoogle Scholar
  9. 9.
    Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Seo S, Waghmare A, Scott EM, et al. Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality. Haematologica. 2017;102:1120–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–84.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209:1195–204.CrossRefPubMedGoogle Scholar
  14. 14.
    Seo S, Xie H, Leisenring WM, et al. Risk factors for parainfluenza virus lower respiratory tract disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(1):163–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014;123:3263–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis. 2001;3:138–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral infection in adult lung transplant recipients. Chest. 1998;113:944–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Vilchez R, McCurry K, Dauber J, et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation. 2002;73:1075–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Lopez-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007;84:851–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:657–66.CrossRefPubMedGoogle Scholar
  21. 21.
    Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP 3rd. Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med. 2003;24:499–530.CrossRefPubMedGoogle Scholar
  22. 22.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation. 2009;87:1530–7.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006;28:131–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect. 2002;17:310–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation. 2010;89:1028–33.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12:38–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016;62:313–9.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193:1619–25.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Versluys AB, Rossen JW, van Ewijk B, Schuurman R, Bierings MB, Boelens JJ. Strong association between respiratory viral infection early after hematopoietic stem cell transplantation and the development of life-threatening acute and chronic alloimmune lung syndromes. Biol Blood Marrow Transplant. 2010;16:782–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1072–8.CrossRefGoogle Scholar
  34. 34.
    Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:S106–14.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gerna G, Vitulo P, Rovida F, et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol. 2006;78:408–16.CrossRefPubMedGoogle Scholar
  36. 36.
    Larcher C, Geltner C, Fischer H, Nachbaur D, Muller LC, Huemer HP. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant. 2005;24:1891–901.CrossRefPubMedGoogle Scholar
  37. 37.
    McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–53.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–28.CrossRefPubMedGoogle Scholar
  39. 39.
    Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000;137:865–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis. 2009;200:1242–6.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004;189:233–8.CrossRefPubMedGoogle Scholar
  42. 42.
    CDC. Respiratory syncytial virus activity – United States, July 2008-December 2009. MMWR Morb Mortal Wkly Rep. 2010;59:230–3.Google Scholar
  43. 43.
    Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001;33:792–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28:222–42.CrossRefGoogle Scholar
  45. 45.
    Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32:471–93.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–67.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755–63.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46:558–66.CrossRefPubMedGoogle Scholar
  49. 49.
    Waghmare A, Xie H, Kimball L, et al. Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus. J Infect Dis. 2017;216:1235–44.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Anderson NW, Binnicker MJ, Harris DM, et al. Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review. Diagn Microbiol Infect Dis. 2016;85:367–71.CrossRefPubMedGoogle Scholar
  51. 51.
    Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplantation recipients. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy760. [Epub ahead of print].CrossRefGoogle Scholar
  52. 52.
    Pilie P, Werbel WA, Riddell J, Shu X, Schaubel D, Gregg KS. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis. 2015;17:551–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013;57:1731–41.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68:1872–80.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11:781–96.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis. 2012;14:64–71.CrossRefPubMedGoogle Scholar
  58. 58.
    Uckay I, Gasche-Soccal PM, Kaiser L, et al. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant. 2010;29:299–305.CrossRefPubMedGoogle Scholar
  59. 59.
    Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308:1443–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Graci JD, Cameron CE. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology. 2002;298:175–80.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother. 2001;12:261–72.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Sookoian S, Castano G, Flichman D, Cello J. Effects of ribavirin on cytokine production of recall antigens and phytohemaglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production). Ann Hepatol. 2004;3:104–7.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994;125:635–41.CrossRefPubMedGoogle Scholar
  64. 64.
    Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119:2738–45; quiz 969.CrossRefPubMedGoogle Scholar
  65. 65.
    Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012;206:1367–71.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56:258–66.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Newborn AAoPCoIDaCoFa. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998;102:1211–6.CrossRefGoogle Scholar
  68. 68.
    Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350–4.CrossRefPubMedGoogle Scholar
  69. 69.
    Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245–9.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:321–7.CrossRefPubMedGoogle Scholar
  71. 71.
    McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis. 2011;13:117–21.CrossRefPubMedGoogle Scholar
  72. 72.
    Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol. 2009;146:574–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19:589–96.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1019–24.CrossRefPubMedGoogle Scholar
  75. 75.
    Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis. 2016;18:634–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008;46:402–12.CrossRefPubMedGoogle Scholar
  77. 77.
    Marcelin JR, Wilson JW, Razonable RR, Mayo Clinic HO. Transplant Infectious Diseases S. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014;16:242–50.CrossRefPubMedGoogle Scholar
  78. 78.
    Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018;20:e12844.CrossRefPubMedGoogle Scholar
  79. 79.
    Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18:210–5.CrossRefPubMedGoogle Scholar
  80. 80.
    Luo YH, Huang CY, Yang KY, Lee YC. Inhaled ribavirin therapy in adult respiratory syncytial virus-induced acute respiratory distress syndrome. Arch Bronconeumol. 2011;47:315–7.CrossRefPubMedGoogle Scholar
  81. 81.
    Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28:67–71.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther. 2011;16:733–40.CrossRefPubMedGoogle Scholar
  83. 83.
    Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839–44.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–9.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Gottlieb J, Torres F, Haddad T, et al. Respiratory syncytial virus (RSV) in lung transplant (LT) recipients. J Heart Lung Transplant. 2018;37:S155.CrossRefGoogle Scholar
  86. 86.
    Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis. 2001;32:413–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996;23:1033–7.CrossRefPubMedGoogle Scholar
  88. 88.
    Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant. 2003;3:116–20.CrossRefPubMedGoogle Scholar
  89. 89.
    Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis. 1993;12:699–701.CrossRefPubMedGoogle Scholar
  90. 90.
    Ustun C, Slaby J, Shanley RM, et al. Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Biol Blood Marrow Transplant. 2012;18:1580–8.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110:1681–8.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–66.CrossRefPubMedGoogle Scholar
  93. 93.
    Garbino J, Gerbase MW, Wunderli W, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest. 2004;125:1033–9.CrossRefPubMedGoogle Scholar
  94. 94.
    Maziarz RT, Sridharan P, Slater S, et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2010;16:192–8.CrossRefPubMedGoogle Scholar
  95. 95.
    Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992;326:921–6.CrossRefPubMedGoogle Scholar
  96. 96.
    Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2001;28:759–63.CrossRefPubMedGoogle Scholar
  97. 97.
    Shima T, Yoshimoto G, Nonami A, et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol. 2008;88:336–40.CrossRefPubMedGoogle Scholar
  98. 98.
    Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis. 2000;31:1516–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Cobian L, Houston S, Greene J, Sinnott JT. Parainfluenza virus respiratory infection after heart transplantation: successful treatment with ribavirin. Clin Infect Dis. 1995;21:1040–1.CrossRefPubMedGoogle Scholar
  100. 100.
    Wright JJ, O'Driscoll G. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone. J Heart Lung Transplant. 2005;24:343–6.CrossRefPubMedGoogle Scholar
  101. 101.
    Park SY, Sung H, Park KT, et al. Parainfluenza virus 3 pneumonia in a kidney transplant recipient. Transpl Infect Dis. 2009;11:333–6.CrossRefPubMedGoogle Scholar
  102. 102.
    Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis. 2011;53:e77–80.CrossRefPubMedGoogle Scholar
  103. 103.
    Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis. 2012;14(4):427–33.CrossRefPubMedGoogle Scholar
  104. 104.
    Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis. 2013;15:E28–32.CrossRefPubMedGoogle Scholar
  105. 105.
    Chalkias S, Mackenzie MR, Gay C, et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis. 2014;16:141–4.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for treatment of Parainfluenza virus infections in Hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant. 2016;22:965–70.CrossRefPubMedGoogle Scholar
  107. 107.
    van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–24.CrossRefPubMedGoogle Scholar
  108. 108.
    Kroll JL, Weinberg A. Human metapneumovirus. Semin Respir Crit Care Med. 2011;32:447–53.CrossRefPubMedGoogle Scholar
  109. 109.
    Biacchesi S, Skiadopoulos MH, Boivin G, et al. Genetic diversity between human metapneumovirus subgroups. Virology. 2003;315:1–9.CrossRefPubMedGoogle Scholar
  110. 110.
    Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443–50.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Falsey AR. Human metapneumovirus infection in adults. Pediatr Infect Dis J. 2008;27:S80–3.CrossRefPubMedGoogle Scholar
  112. 112.
    Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 2003;187:785–90.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168:2489–96.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Debur MC, Vidal LR, Stroparo E, et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12:173–9.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Englund JA, Boeckh M, Kuypers J, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344–9.CrossRefGoogle Scholar
  116. 116.
    Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis. 2005;192:1061–5.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Oliveira R, Machado A, Tateno A, Boas LV, Pannuti C, Machado C. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant. 2008;42:265–9.CrossRefPubMedGoogle Scholar
  118. 118.
    Shah DP, Shah PK, Azzi JM, El Chaer F, Chemaly RF. Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Lett. 2016;379:100–6.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Seo S, Gooley TA, Kuypers JM, et al. Human metapneumovirus infections following hematopoietic cell transplantation: Factors associated with disease progression. Clin Infect Dis. 2016;63:178–85.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178:876–81.CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antivir Res. 2003;60:51–9.CrossRefPubMedGoogle Scholar
  122. 122.
    Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50:774–7.CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. 2009;145:667–9.CrossRefPubMedGoogle Scholar
  124. 124.
    Shachor-Meyouhas Y, Ben-Barak A, Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr Blood Cancer. 2011;57:350–1.CrossRefPubMedGoogle Scholar
  125. 125.
    Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13:324–8.CrossRefPubMedGoogle Scholar
  126. 126.
    Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26:862–4.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Williams JV, Chen Z, Cseke G, et al. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J Virol. 2007;81:8315–24.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Ulbrandt ND, Ji H, Patel NK, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006;80:7799–806.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008;52:279–87.CrossRefPubMedGoogle Scholar
  130. 130.
    Kanne JP, Godwin JD, Franquet T, Escuissato DL, Muller NL. Viral pneumonia after hematopoietic stem cell transplantation: high-resolution CT findings. J Thorac Imaging. 2007;22:292–9.CrossRefPubMedGoogle Scholar
  131. 131.
    Ko JP, Shepard JA, Sproule MW, et al. CT manifestations of respiratory syncytial virus infection in lung transplant recipients. J Comput Assist Tomogr. 2000;24:235–41.CrossRefPubMedGoogle Scholar
  132. 132.
    Ferguson PE, Sorrell TC, Bradstock KF, Carr P, Gilroy NM. Parainfluenza virus type 3 Pneumonia in bone marrow transplant recipients: multiple small nodules in high-resolution lung computed tomography scans provide a radiological clue to diagnosis. Clin Infect Dis. 2009;48(7):905–9.CrossRefPubMedGoogle Scholar
  133. 133.
    Franquet T, Rodriguez S, Martino R, Salinas T, Gimenez A, Hidalgo A. Human metapneumovirus infection in hematopoietic stem cell transplant recipients: high-resolution computed tomography findings. J Comput Assist Tomogr. 2005;29:223–7.CrossRefPubMedGoogle Scholar
  134. 134.
    Franquet T, Rodriguez S, Martino R, Gimenez A, Salinas T, Hidalgo A. Thin-section CT findings in hematopoietic stem cell transplantation recipients with respiratory virus pneumonia. AJR Am J Roentgenol. 2006;187:1085–90.CrossRefPubMedGoogle Scholar
  135. 135.
    Escuissato DL, Gasparetto EL, Marchiori E, et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol. 2005;185:608–15.CrossRefPubMedGoogle Scholar
  136. 136.
    Gasparetto EL, Escuissato DL, Marchiori E, Ono S, Frare e Silva RL, Muller NL. High-resolution CT findings of respiratory syncytial virus pneumonia after bone marrow transplantation. AJR Am J Roentgenol. 2004;182:1133–7.CrossRefPubMedGoogle Scholar
  137. 137.
    Kamboj M, Gerbin M, Huang CK, et al. Clinical characterization of human metapneumovirus infection among patients with cancer. J Infect. 2008;57:464–71.CrossRefPubMedGoogle Scholar
  138. 138.
    Miller WT Jr, Barbosa E Jr, Mickus TJ, Mullin C, Van Deerlin VM, Shiley KT. Chest computed tomographic imaging characteristics of viral acute lower respiratory tract illnesses: a case-control study. J Comput Assist Tomogr. 2011;35:524–30.CrossRefPubMedGoogle Scholar
  139. 139.
    Shiley KT, Van Deerlin VM, Miller WT Jr. Chest CT features of community-acquired respiratory viral infections in adult inpatients with lower respiratory tract infections. J Thorac Imaging. 2010;25:68–75.CrossRefPubMedGoogle Scholar
  140. 140.
    Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev. 2008;21:716–47.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Fan J, Henrickson KJ. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay. J Clin Microbiol. 1996;34:1914–7.PubMedPubMedCentralGoogle Scholar
  142. 142.
    Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis. 1998;26:1397–402.CrossRefPubMedGoogle Scholar
  143. 143.
    Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis. 2009;11:298–303.CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48:217–49.CrossRefPubMedGoogle Scholar
  145. 145.
    Hammond SP, Gagne LS, Stock SR, et al. Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol. 2012;50:3216–21.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One. 2011;6:e26047.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44:453–5.CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Hall CB, Douglas RG Jr, Schnabel KC, Geiman JM. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun. 1981;33:779–83.PubMedPubMedCentralGoogle Scholar
  149. 149.
    Jalal H, Bibby DF, Bennett J, et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol. 2007;45:1690–6.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant. 2010;16:1265–71.CrossRefPubMedGoogle Scholar
  151. 151.
    Sydnor ER, Greer A, Budd AP, et al. An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. Am J Infect Control. 2012;40(7):601–5.CrossRefPubMedGoogle Scholar
  152. 152.
    Tu CC, Chen LK, Lee YS, et al. An outbreak of human metapneumovirus infection in hospitalized psychiatric adult patients in Taiwan. Scand J Infect Dis. 2009;41:363–7.CrossRefPubMedGoogle Scholar
  153. 153.
    Nichols WG, Erdman DD, Han A, Zukerman C, Corey L, Boeckh M. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant. 2004;10:58–64.CrossRefPubMedGoogle Scholar
  154. 154.
    Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53:1–36.PubMedPubMedCentralGoogle Scholar
  155. 155.
    Yokoe D, Casper C, Dubberke E, et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant. 2009;44:495–507.CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
  157. 157.
    Cortez K, Murphy BR, Almeida KN, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis. 2002;186:834–8.CrossRefPubMedGoogle Scholar
  158. 158.
    Le Bayon JC, Lina B, Rosa-Calatrava M, Boivin G. Recent developments with live-attenuated recombinant paramyxovirus vaccines. Rev Med Virol. 2013;23(1):15–34.CrossRefPubMedGoogle Scholar
  159. 159.
    Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017;23:107–12.CrossRefPubMedPubMedCentralGoogle Scholar
  160. 160.
    Marquez-Escobar VA. Current developments and prospects on human metapneumovirus vaccines. Expert Rev Vaccines. 2017;16:419–31.CrossRefPubMedGoogle Scholar
  161. 161.
    Pawelczyk M, Kowalski ML. The role of human Parainfluenza virus infections in the immunopathology of the respiratory tract. Curr Allergy Asthma Rep. 2017;17:16.CrossRefPubMedGoogle Scholar
  162. 162.
    Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis. 2004;39:673–80.CrossRefPubMedGoogle Scholar
  163. 163.
    Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:2682–92.CrossRefPubMedPubMedCentralGoogle Scholar
  164. 164.
    Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11:2020–30.CrossRefPubMedPubMedCentralGoogle Scholar
  165. 165.
    Ng BJ, Glanville AR, Snell G, et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant. 2011;11:568–74.CrossRefPubMedGoogle Scholar
  166. 166.
    Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2:287–91.CrossRefPubMedPubMedCentralGoogle Scholar
  167. 167.
    Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117:5050–6.CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant. 2011;17:979–86.CrossRefPubMedGoogle Scholar
  169. 169.
    Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10:521–6.CrossRefPubMedPubMedCentralGoogle Scholar
  170. 170.
    Ljungman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96:1231–5.CrossRefPubMedPubMedCentralGoogle Scholar
  171. 171.
    Elicker BM, Schwartz BS, Liu C, et al. Thoracic CT findings of novel influenza A (H1N1) infection in immunocompromised patients. Emerg Radiol. 2010;17:299–307.CrossRefPubMedPubMedCentralGoogle Scholar
  172. 172.
    Cordero E, Perez-Romero P, Moreno A, et al. Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin Microbiol Infect. 2012;18:67–73.CrossRefPubMedGoogle Scholar
  173. 173.
    Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis. 2011;203:1739–47.CrossRefPubMedGoogle Scholar
  174. 174.
    Liu C, Schwartz BS, Vallabhaneni S, et al. Pandemic (H1N1) 2009 infection in patients with hematologic malignancy. Emerg Infect Dis. 2010;16:1910–7.CrossRefPubMedPubMedCentralGoogle Scholar
  175. 175.
    Beutel G, Wiesner O, Eder M, et al. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care. 2011;15:R80.CrossRefPubMedPubMedCentralGoogle Scholar
  176. 176.
    Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11:1071–8.CrossRefGoogle Scholar
  177. 177.
    Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500.CrossRefPubMedGoogle Scholar
  178. 178.
    Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis. 2010;50:707–14.CrossRefPubMedPubMedCentralGoogle Scholar
  179. 179.
    Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11:100–5.CrossRefPubMedGoogle Scholar
  180. 180.
    Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003–32.CrossRefPubMedPubMedCentralGoogle Scholar
  181. 181.
    Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009;360:953–6.CrossRefPubMedGoogle Scholar
  182. 182.
    Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 2011;16.Google Scholar
  183. 183.
    Centers for Disease Control. Flu. www.cdc.gov/flu. Accessed Sept 2018.
  184. 184.
    Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193:760–4.CrossRefPubMedGoogle Scholar
  185. 185.
    Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8.CrossRefPubMedGoogle Scholar
  186. 186.
    Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011;17:255–7.CrossRefPubMedPubMedCentralGoogle Scholar
  187. 187.
    McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75.CrossRefPubMedGoogle Scholar
  188. 188.
    Machado CM. Influenza infections after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;41:273–4.CrossRefPubMedGoogle Scholar
  189. 189.
    Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood. 2010;115:1331–42.CrossRefPubMedPubMedCentralGoogle Scholar
  190. 190.
    Ison MG, Michaels MG. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S166–72.CrossRefPubMedPubMedCentralGoogle Scholar
  191. 191.
    Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant. 2010;10:18–25.CrossRefPubMedPubMedCentralGoogle Scholar
  192. 192.
    Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845–50.CrossRefPubMedGoogle Scholar
  193. 193.
    Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24.CrossRefPubMedGoogle Scholar
  194. 194.
    Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses. 2013;7(Suppl 3):60–6.CrossRefPubMedPubMedCentralGoogle Scholar
  195. 195.
    Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis. 2017;17:1255–65.CrossRefPubMedPubMedCentralGoogle Scholar
  196. 196.
    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.CrossRefPubMedGoogle Scholar
  197. 197.
    Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36:897–900.CrossRefPubMedGoogle Scholar
  198. 198.
    DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–45.CrossRefPubMedGoogle Scholar
  199. 199.
    Halasa NB, Savani BN, Asokan I, et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant. 2016;22:528–35.CrossRefPubMedGoogle Scholar
  200. 200.
    Chong PP, Handler L, Weber DJ. A systematic review of safety and immunogenicity of influenza vaccination strategies in solid organ transplant recipients. Clin Infect Dis. 2018;66:1802–11.CrossRefPubMedGoogle Scholar
  201. 201.
    Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66:1698–704.CrossRefPubMedGoogle Scholar
  202. 202.
    Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev. 2010:CD005187.Google Scholar
  203. 203.
    Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a Novel Coronavirus from a man with Pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–20.CrossRefPubMedGoogle Scholar
  204. 204.
    de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523–34.CrossRefPubMedGoogle Scholar
  205. 205.
    Uhlenhaut C, Cohen JI, Pavletic S, et al. Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia. Transpl Infect Dis. 2012;14:79–85.CrossRefPubMedGoogle Scholar
  206. 206.
    Oosterhof L, Christensen CB, Sengelov H. Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient. Bone Marrow Transplant. 2010;45:1115–6.CrossRefPubMedGoogle Scholar
  207. 207.
    Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant. 2007;40:809–11.CrossRefPubMedGoogle Scholar
  208. 208.
    Ogimi C, Waghmare AA, Kuypers JM, et al. Clinical significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2017;64:1532–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Fred Hutchinson Cancer Research Center, University of Washington Medical CenterSeattleUSA
  2. 2.Division of Infectious Diseases and Geographic MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations